Other
Stock Issuance Proceeds
Gilead Sciences Stock Issuance Proceeds increased by 418.8% to $166.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 34.1%, from $252.00M to $166.00M. Over 4 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows an upward trend with a 24.7% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 7, 2026
How to read this metric
An increase suggests the company is raising capital through equity, while a decrease indicates a reduction in equity-based financing.
Detailed definition
Represents the cash inflows received by the company from the issuance of new common equity shares to investors or employ...
Peer comparison
Standard line item in the financing section of the cash flow statement for all public companies.
Metric ID:
other_proceeds_from_issuance_of_common_stockHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.00M | $57.00M | $12.00M | $94.00M | $3.00M | $36.00M | $176.00M | $97.00M | $26.00M | $83.00M | $26.00M | $146.00M | $5.00M | $98.00M | $173.00M | $252.00M | $27.00M | $97.00M | $32.00M | $166.00M |
| QoQ Change | — | +375.0% | -78.9% | +683.3% | -96.8% | >999% | +388.9% | -44.9% | -73.2% | +219.2% | -68.7% | +461.5% | -96.6% | >999% | +76.5% | +45.7% | -89.3% | +259.3% | -67.0% | +418.8% |
| YoY Change | — | — | — | — | -75.0% | -36.8% | >999% | +3.2% | +766.7% | +130.6% | -85.2% | +50.5% | -80.8% | +18.1% | +565.4% | +72.6% | +440.0% | -1.0% | -81.5% | -34.1% |
Range$3.00M – $252.00M
CAGR+73.9%
Avg YoY Growth+188.7%
Median YoY Growth+10.6%
Stock Issuance Proceeds at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's stock issuance proceeds?
- Gilead Sciences (GILD) reported stock issuance proceeds of $166.00M in Q1 2026.
- How has Gilead Sciences's stock issuance proceeds changed year-over-year?
- Gilead Sciences's stock issuance proceeds decreased by 34.1% year-over-year, from $252.00M to $166.00M.
- What is the long-term trend for Gilead Sciences's stock issuance proceeds?
- Over 4 years (2021 to 2025), Gilead Sciences's stock issuance proceeds has grown at a 24.7% compound annual growth rate (CAGR), from $169.00M to $408.00M.
- What does stock issuance proceeds mean?
- Cash received from selling new shares of common stock.